The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Interesting to see if this encourages other countries to adopt the same approach. In isolation the UK isn't going to incentivise a company to develop an antimicrobial (the UK is a small proportion of the global market) but interesting to see if taking the lead gets others to follow? Really just need the US to take a similar approach now with DISARM - knowing the US though they like to lead rather than follow...
As a pilot, in isolation, it's unlikely to change much (the payment from the NHS/UK won't touch the sides of the development costs) but someone has to do something, so lets hope we see the approach adopted elsewhere.
do we know if it's a 900k buy or sell, when they only give the mid price? Seeing a few of these going through recently..
Jemmolly - best look through the RNS's - relevant link below
https://www.londonstockexchange.com/exchange/news/market-news/market-news-detail/BXP/13941924.html
The 12.5% paid to shareholders equated to 1.25Tk per share (see RNS). As AIM holds GDR's, which = 10 shares, we were paid 12.5Tk per share (mine showed up in USDs).
The Taka has increased in strength to the pound and thus 12.5 taka at today's exchange rate = 1.176p. As a note if the dividend does increase to 15% (and that's only a guesstimate as not declared yet - but final year results likely to reflect Q3) this would equate to 1.411p per AIM share (GDR) and thus a c4% yield on today's SP, if they hold at 12.5% it will equal 3.3%..
You could be right gharri - I was half joking when I mentioned Woodford but is there a way to find out if he held?
Just need to wait for BXPs seller to finish up and the SP to bottom out..If we see a an increase in dividend (as some predicting) from the 12.5% paid last year to 15% this year - at today's SP that would equate to a 4% dividend yield.
also has very little analyst coverage over here..
Woodford didn't have any did he?
As it's holding up well on the Dhaka @84 (78.5p equivalent on AIM) I'm personally not worried, and reckon they would have more insight in Bangladesh than we do over here to anything sinister. This is currently my largest holding but it's a long term hold. Historically it doesn't seem to do so well in June/July but has an uplift when the final year results are released (which will be Nov 7th this year). Expecting a decent dividend (+3% yield on today's SP) and uplift/correction later this year..
I wonder if the old adage "sell in May and go away" is at play? We could have a new one here "Buy in July and wait for the high" (on final year results)..
Game of patience and guess it's just MM's moving it on very low volume (but others will know more than me on their shenanigans)?
there is + also provides the dividend yield based on today's price (c3%)
Hi YoungHarry - just had another look, in case I missed it - states (as it did on clinicaltrials.gov)
"The effect of Lupuzor™ in the Clinical SLEDAI-2K total score at final visit compared to initial visit"..
Where are you looking to say "initial visit for the open study was used as the baseline"? They probably did but it's unusual to do a response analysis this way - you'd have to show a response on top of a response already achieved before entry. Typically it would be presented as a "maintenance of response" based on the initial study entry (P3) score being used as baseline..
Given how close the remission rates are to the response rates it does look like baseline (initial visit) may well have been the start of the extension. If they'd used the P3 baseline (as they should have) they would probably have seen double the response rates - surprised they didn't go down this line.
I sold on market opening so no longer hold..
Good remission rates at 32%. The company should clarify what baseline (initial visit) they're using for "response". If they've used the start of the extension study as the baseline score the "response" rates are likely to be much lower than if they'd used the start of the P3 (where all patients have a SLEDAI 2k >6 at baseline).
They should use the baseline of the randomised P3 but not sure if they have - this may provide higher "response" rates? For "remission" the baseline questions doesn't matter.
I sold before the -ve P3 results (but did ok) and thought I would take a punt again today. The probability of the extension study yielding something that can tell a positive story is high, I believe (it's open label and naturally selecting patients who were most likely doing well). How much the SP will react I don't know. I'm not so strong on the financials but given that if the SP raises above the 13.33 benchmark, IMM will get 100% of the agreed amount + the % over the benchmark (I think I've read that correctly) - they may well be confident (or know) the results and hope the trial will give a lift to the SP over the benchmark? Maybe they felt they could raise more this way than wait till after the newsflow? but actually I've no idea - just hoping now
Last year was USD 1.49 cents per share, as long as you were on the books in Nov..
Yes - cash, as long as you're a holder on the November cut-off. The actual amount has not been declared yet but some predicting it may be slightly higher than last year.
It is hard to understand the SP when net sales in 2016/17 where £147m, followed by £160m in 17/18 and now looking to be >£210m for 18/19 - well above any other year, as are profits (from what we can see)... currently trading on the Dhaka at 74p equivalent but AIM stuck below 40p .. Does anyone have any inkling as to why?
https://endpts.com/in-starved-antibiotic-field-melinta-soars-as-fda-grants-speedy-drug-review/
Thank you Chris and Waterloo01...
I had a quick look at the DISARM 2019 act again and, on my quick read, it looked like it was effective (after public consultation) on the 1st of Oct 2020 - and providing 106% now, instead of 102%. I might have misunderstood it though? Link to the bill below..
https://www.isakson.senate.gov/public/_cache/files/244e41a8-9d38-4024-9783-a1511c133816/06-04-19%20DISARM%20116th%20Congress.pdf
With all the generics companies named and shamed in the US now we know BXP definitely is not one of them (would have been very surprised if it was)..
https://assets.documentcloud.org/documents/5997883/GENERIC-DRUGS-COMPLAINT.pdf
BXP Final year results will be out in early November and we should see reported revenues around 27-28% higher than last year, with an increase in EPS of around 15-20% (all based on Q3 results) ... so should hopefully see SP go above 50p, maybe not til their announcement, but none the less that would give a >20% SP gain in <5 months (+ dividends will be announced to any holder on the Nov cut-off date)..
RNS 12th June
"Recruitment of patients into the two Phase 3 clinical trials is ongoing, and the programme remains on-track for expected reporting of top-line data in H2 2021"...
We should get more updates on recruitment as the trial progresses.. - I'd hope at least
Thanks Chris - look forward to hearing how it goes, and as you say they can't really give any substantial updates without an RNS... hopefully we'll start seeing a recovery soon..
Hi Chris - are you by any chance going to the AGM? May (hopefully) be some new updates there? Unfortunately I can't attend..